Long-term immunosuppression in transplant recipients is associated with important adverse effects including increased risk of infection and malignancy. New data from the ONE Study suggests that use of cell-based medicinal products containing regulatory immune cells is a potentially useful therapeutic strategy to enable minimization of immunosuppression in these patients.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sawitzki, B. et al. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet 395, 1627–1639 (2020).
Sasaki, H. et al. Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach. Hum. Immunol. 79, 258–265 (2018).
Sykes, M. Immune monitoring of transplant patients in transient mixed chimerism tolerance trials. Hum. Immunol. 79, 334–342 (2018).
Scandling, J. D. et al. Macrochimerism and clinical transplant tolerance. Hum. Immunol. 79, 266–271 (2018).
Leventhal, J. R. et al. Updated follow-up of a tolerance protocol in HLA-identical renal transplant pairs given donor hematopoietic stem cells. Hum. Immunol. 79, 277–282 (2018).
Leventhal, J. R. & Ildstad, S. T. Tolerance induction in HLA disparate living donor kidney transplantation by facilitating cell-enriched donor stem cell Infusion: the importance of durable chimerism. Hum. Immunol. 79, 272–276 (2018).
Leventhal, J. R. & Mathew, J. M. Outstanding questions in transplantation: tolerance. Am. J. Transplant. 20, 348–354 (2020).
Levitsky, J. et al. Immunosuppression withdrawal in liver transplant recipients on sirolimus. Hepatology https://doi.org/10.1002/hep.31036 (2019).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Mathew, J.M., Leventhal, J.R. Cell therapy can enable minimization of immunosuppression. Nat Rev Nephrol 16, 486–487 (2020). https://doi.org/10.1038/s41581-020-0330-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-020-0330-5